Abstract
Mesenchymal stem cells (MSCs) possess many properties that may make them suitable as transplanted therapeutic agents for ischemia/reperfusion injury (I/R). These properties include but are not limited to paracrine signaling [1], immunomodulation of the recipient environment [2, 3], and possibly differentiation into the injured tissue [4]. Several studies have investigated the effects of MSCs with respect to I/R of the heart [5], brain [6], and kidney [7]. However, the role of MSCs has not been determined in the setting of intestinal I/R.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
